由于其罕见的适应症、技术困难和并发症率高的担忧，机器人辅助胰腺中央切除术并不常见。我们回顾了2016年5月至2021年6月在单一机构进行的六例机器人辅助胰腺中央切除术病例。本多媒体文章旨在介绍我们的机器人辅助胰腺中央切除术技术及围手术期和随访结果。所有患者均出现了术后胰腺瘘生化泄漏，仅一例为B级胰腺瘘，导致假性囊肿形成，通过内镜内引流成功处理。所有患者均达到完全负性切缘。在中位随访期为13.5个月（范围10-74个月）期间，没有新发生的糖尿病或复发。在可接受的并发症率和胰腺功能保护下，机器人辅助胰腺中央切除术可能是胰腺颈部或近端体部的良性和边缘恶性肿瘤患者的良好手术选择。

Robotic central pancreatectomy has not been widely performed because of its rare indications, technical difficulties, and concern about the high complication rate. We reviewed six robotic central pancreatectomy cases between May 2016 and June 2021 at a single institution. This multimedia article aims to introduce our technique of robotic central pancreatectomy with perioperative and follow-up outcomes. All patients experienced biochemical leakage of postoperative pancreatic fistula, except in one with a grade B pancreatic fistula, which resulted in a pseudocyst formation and was successfully managed by endoscopic internal drainage. All patients achieved completely negative resection margins. There was no new-onset diabetes mellitus or recurrence during the median follow-up period of 13.5 months (range, 10-74 months). With an acceptable complication rate and the preservation of pancreatic function, robotic central pancreatectomy could be a good surgical option for patients with benign and borderline malignant tumors of the pancreatic neck or proximal body.